By
Trending Posts
Will Novartis’ $280M Gene Therapy Plant Transform Denton…
Denton, TX The Denton City Council has unanimously approved an economic development agreement with Novartis Gene Therapies, paving…
Will Novo Nordisk Pull Ahead of Eli Lilly…
The U.S. Food and Drug Administration (FDA) has approved the first daily oral version of the obesity drug…
Is Tanya Alcorn Poised to Transform Pfizer’s Global…
Pfizer has appointed Tanya Alcorn as President, Global Hospital and Biosimilars, expanding her leadership responsibilities after serving more…
Is Pfizer Facing New Safety Scrutiny After Reporting…
Pfizer has disclosed that a patient enrolled in a clinical trial evaluating its investigational hemophilia treatment Hympavzi died…
How Is Pfizer Expanding Its Oncology Pipeline Through…
Cambridge, Massachusetts Pfizer is strengthening its oncology research pipeline through a new program launched under its strategic collaboration…
Will AI-Powered Prior Authorization Change How Medicare Care…
December 2025 — Medicare is preparing to introduce artificial intelligence–driven prior authorization reviews for certain medical services beginning…
Did 2025 Expose the Breaking Point of America’s…
New reflections from healthcare leaders highlight how events in 2025 revealed deep structural weaknesses in the U.S. health…
How Is Senhwa Biosciences Using AI and Strategic…
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
Will the European Commission’s New Health Policy Package…
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
Trending Posts
Latest Stories
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation…
Can Merck Redefine Its Growth Story Beyond Keytruda as the Patent Clock Ticks?
Late January 2026 | Full-Year 2025 Earnings Preview | Oncology, Vaccines & Post-Keytruda Strategy Merck…
Can Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is…
Gallery
